Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (2)

Search Parameters:
Keywords = immunoglobulin/histamine complex

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
15 pages, 758 KB  
Review
Histamine-Mediated Syndrome (HMS): Beyond Allergy and Therapeutic Potential of Immunoglobulin/Histamine Complex (IHC)
by Hyuk Soon Kim and Geunwoong Noh
Int. J. Mol. Sci. 2026, 27(10), 4494; https://doi.org/10.3390/ijms27104494 - 17 May 2026
Abstract
Histamine, present in almost all tissues, exerts diverse biologic actions through four receptors expressed across multiple organs and cell types. Histamine concentrations are elevated in various conditions. A wide spectrum of clinical manifestations where histamine levels increase has been described. When plasma histamine [...] Read more.
Histamine, present in almost all tissues, exerts diverse biologic actions through four receptors expressed across multiple organs and cell types. Histamine concentrations are elevated in various conditions. A wide spectrum of clinical manifestations where histamine levels increase has been described. When plasma histamine concentrations are increased, multiple symptoms may occur via histamine receptor-mediated signaling. These clinical situations are defined as histamine-mediated syndrome (HMS). Recent reports describe the use of an immunoglobulin/histamine complex (IHC) to treat conditions beyond classical allergic diseases, such as allergic rhinitis (AR) and chronic urticaria (CU). Baseline plasma histamine levels in AR and CU can be higher than expected. This suggests histamine-driven comorbid manifestations in tissues and organs expressing histamine receptors. Accordingly, HMS may be more common in routine practice than is generally appreciated. IHC may represent a rational therapeutic option for HMS. In this review, we define HMS and integrate the available evidence to propose a systematic clinical framework. Full article
Show Figures

Figure 1

10 pages, 1332 KB  
Review
Histamine-Releasing Factor, a New Therapeutic Target in Allergic Diseases
by Yu Kawakami, Kazumi Kasakura and Toshiaki Kawakami
Cells 2019, 8(12), 1515; https://doi.org/10.3390/cells8121515 - 26 Nov 2019
Cited by 23 | Viewed by 7233
Abstract
Histamine-releasing activities on human basophils have been studied as potential allergy-causing agents for four decades. An IgE-dependent histamine-releasing factor (HRF) was recently shown to interact with a subset of immunoglobulins. Peptides or recombinant proteins that block the interactions between HRF and IgE have [...] Read more.
Histamine-releasing activities on human basophils have been studied as potential allergy-causing agents for four decades. An IgE-dependent histamine-releasing factor (HRF) was recently shown to interact with a subset of immunoglobulins. Peptides or recombinant proteins that block the interactions between HRF and IgE have emerged as promising anti-allergic therapeutics, as administration of them prevented or ameliorated type 2 inflammation in animal models of allergic diseases such as asthma and food allergy. Basic and clinical studies support the notion that HRF amplifies IgE-mediated activation of mast cells and basophils. We discuss how secreted HRF promotes allergic inflammation in vitro and in vivo complex disease settings. Full article
(This article belongs to the Special Issue Role of TCTP in Cell Biological and Disease Processes)
Show Figures

Figure 1

Back to TopTop